All In Biotech

NDA 022219 · Endo Operations

Aveed

Testosterone Undecanoate · Intramuscular

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 5, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

82

23 Phase 3, 9 recruiting

FAERS reports

1,547

970 serious, 51 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS PULMONARY OIL MICROEMBOLISM (POME) REACTIONS AND ANAPHYLAXIS Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose [see Warnings and Precautions ( 5.1 )] . Following each injection of AVEED, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis [see Warnings and Precautions ( 5.1 )] . Because of the risks of serious POME reactions and anaphylaxis, AVEED is available only through a restricted...

What it is approved for

From the label in effect Jul 15, 2025.

AVEED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. AVEED should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of POME and anaphylaxis. Limitations of Use Safety and efficacy of AVEED in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of AVEED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )]. Aveed (testosterone undecanoate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Aveed should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of...

Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; and alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AVEED · TESTOSTERONE UNDECANOATE 750MG/3ML (250MG/ML) · INJECTABLE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone Undecanoate" as an intervention, any sponsor and status, largest first.

All 82 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective231
  • cough153
  • off label use134
  • dyspnoea107
  • pulmonary oil microembolism84
  • blood testosterone decreased65
  • fatigue57
  • dizziness52
  • injection site pain52
  • hyperhidrosis48
  • asthenia47
  • malaise41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20061
20093
20106
20112
20129
20135
2014120
2015232
2016142
201798
2018154
2019140
2020136
2021104
202276
202362
202441
2025132
202681

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aveed (Testosterone Undecanoate)

2024 spending

$1.6M

Beneficiaries

246

846 claims

Per beneficiary

$6,423

$622.58 per unit

View as table
YearSpending
2020$862,494
2021$987,039
2022$1,066,080
2023$1,322,290
2024$1,580,109

Part B: Aveed (Testosterone Undecanoate) · HCPCS J3145

2024 spending

$19.9M

Beneficiaries

3,821

14,649 claims

Per beneficiary

$5,219

2024 ASP limit $1.90 per unit

View as table
YearSpending
2020$13,078,429
2021$14,826,933
2022$16,473,381
2023$18,639,276
2024$19,943,400

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 217 on PubMed

Sponsor: Endo Operations

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.